ETF PROAI

IDEVvsIHE

iShares Core MSCI International Developed Markets ETF against iShares U.S. Pharmaceuticals ETF — the fee, the flows, the book, and a year head-to-head.

One year, growth of $100
IDEV 110IHE 130Oct 25Oct 26GROWTH OF $100
Head to head
IDEVIHE
Expense ratio0.040%0.40%
Assets$32.2B$1.6B
Net flow, 1 month+$614M+$25M
Net flow, 1 year+$6.9B+$795M
Return, YTD+8.6%+16.3%
Return, 1 year+9.9%+30.5%
Avg daily volume2.5M177K
Holdings228138
ListedMar 21, 2017May 1, 2006
Options marketYesYes

MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS

THE DESK BRIEF

Flows, fee cuts, and closure risk on the funds you watch — every trading morning.